| Browse All

Virax Biolabs Group Limited (VRAX)

Healthcare | Biotechnology | Lanarkshire, United Kingdom | NasdaqCM
0.15 USD 0.00 (-1.056%) ⇩ (April 17, 2026, 4 p.m. EDT)
After hours: 0.14 -0.01 (-0.006%) ⇩ (April 17, 2026, 7:58 p.m. EDT)

Short-term: ★☆☆☆☆ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 3:30 p.m. EDT

VRAX (Virax Biolabs Group Limited) presents a highly volatile and uncertain investment profile. The stock has experienced significant price swings, with a recent close of $0.1041, which is near its 52-week low of $0.10. The negative forward PE, trailing EPS, and operating margins suggest poor financial performance and lack of profitability. The stock's low market cap and high debt-to-equity ratio indicate substantial financial risk. While recent news highlights clinical progress and private placements, these are not enough to offset the overall negative fundamentals. The short-term price forecasting model predicts a significant decline, further indicating a bearish outlook. Given the lack of dividends and the overall negative financial indicators, this stock is not suitable for short-term or long-term investment.

Model Selection — Backtest MAE (log-scale, lower is better)
ModelMAE
AutoTheta ✓0.078814
AutoARIMA0.316366
AutoETS0.316375
MSTL0.345159

Forecast horizon: 45 days | Selected: AutoTheta

Forecast Reliability
Score 62%
H-stat 1.93
Ljung-Box p 0.006
Jarque-Bera p 0.545
Excess Kurtosis 0.69
Attribute Value
Sector Healthcare
Debt to Equity Ratio 10.604
Revenue per Share 0.001
Market Cap 1,112,772
Forward P/E -0.62
Beta 1.60
Website https://viraxbiolabs.com

Info Dump

Attribute Value
52 Week Change -0.8335159
Address1 BioCity Glasgow
Address2 Bo’Ness Road Newhouse
All Time High 290.0
All Time Low 0.1
Ask 0.1685
Ask Size 1
Average Daily Volume10 Day 51,719,820
Average Daily Volume3 Month 12,700,285
Average Volume 12,700,285
Average Volume10Days 51,719,820
Beta 1.598
Bid 0.1229
Bid Size 1
Book Value 0.812
City Lanarkshire
Compensation As Of Epoch Date 1,767,139,200
Country United Kingdom
Crypto Tradeable 0
Currency USD
Current Price 0.1499
Current Ratio 11.354
Custom Price Alert Confidence HIGH
Date Short Interest 1,774,915,200
Day High 0.1499
Day Low 0.135
Debt To Equity 10.604
Display Name Virax Biolabs
Ebitda -5,556,497
Ebitda Margins 0.0
Enterprise To Ebitda 0.388
Enterprise To Revenue -722.526
Enterprise Value -2,157,463
Eps Current Year -0.4
Eps Forward -0.24
Eps Trailing Twelve Months -1.22
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Day Average 0.19338
Fifty Day Average Change -0.043479994
Fifty Day Average Change Percent -0.22484225
Fifty Two Week Change Percent -83.351585
Fifty Two Week High 1.2
Fifty Two Week High Change -1.0501001
Fifty Two Week High Change Percent -0.8750834
Fifty Two Week Low 0.1
Fifty Two Week Low Change 0.049900003
Fifty Two Week Low Change Percent 0.499
Fifty Two Week Range 0.1 - 1.2
Financial Currency USD
First Trade Date Milliseconds 1,658,410,200,000
Float Shares 5,502,241
Forward Eps -0.24
Forward P E -0.62458336
Free Cashflow -3,539,977
Full Exchange Name NasdaqCM
Full Time Employees 19
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Gross Profits -45,306
Has Pre Post Market Data 1
Held Percent Insiders 0.01793
Held Percent Institutions 0.043109998
Implied Shares Outstanding 7,423,432
Industry Biotechnology
Industry Disp Biotechnology
Industry Key biotechnology
Ipo Expected Date 2,022-07-21
Language en-US
Last Fiscal Year End 1,743,379,200
Last Split Date 1,702,857,600
Last Split Factor 1:10
Long Business Summary Virax Biolabs Group Limited, a biotechnology company, distributes diagnostics test kits for the prevention, detection, diagnosis, and risk management of viral diseases in the field of T cell in Vitro Diagnostics. The company offers various in-vitro diagnostics test kits comprising respiratory, pregnancy and fertility, infectious diseases, sti, drugs of abuse, oncology, cardiac, women's health, other test kits under the ViraxClear brands; and rapid and molecular tests for small animal veterinary diagnostics under the ViraxVet brand. It also provides ViraxImmune, a T cell In vitro diagnostic device and wellness mobile application; and service, such as antibody engineering, custom peptides, protein sequencing, vaccine efficacy testing, immunology lab services, kits and reagents. In addition, the company is involved in research and development activities; and provision of procurement, warehousing, product development, and staffing management services. It serves research organizations, corporations, independent laboratories, large hospital systems and public and private institutions, as well as distributor customers. The company operates in the United Kingdom, the United States, and China. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was founded in 2013 and is headquartered in Lanarkshire, the United Kingdom.
Long Name Virax Biolabs Group Limited
Market us_market
Market Cap 1,112,772
Market State CLOSED
Max Age 86,400
Message Board Id finmb_1685878340
Most Recent Quarter 1,759,190,400
Net Income To Common -5,643,591
Next Fiscal Year End 1,774,915,200
Non Diluted Market Cap 1,097,183
Number Of Analyst Opinions 1
Open 0.1476
Operating Cashflow -5,405,240
Operating Margins -1,607.8832
Payout Ratio 0.0
Phone 44 20 7788 7414
Post Market Change -0.0059999973
Post Market Change Percent -4.0026665
Post Market Price 0.1439
Post Market Time 1,776,470,288
Previous Close 0.1515
Price Eps Current Year -0.37475002
Price Hint 4
Price To Book 0.18460593
Price To Sales Trailing12 Months 372.6631
Profit Margins 0.0
Quick Ratio 9.887
Quote Source Name Nasdaq Real Time Price
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change -0.0016
Regular Market Change Percent -1.0561
Regular Market Day High 0.1499
Regular Market Day Low 0.135
Regular Market Day Range 0.135 - 0.1499
Regular Market Open 0.1476
Regular Market Previous Close 0.1515
Regular Market Price 0.1499
Regular Market Time 1,776,456,000
Regular Market Volume 3,166,809
Return On Assets -0.48403
Return On Equity -0.83822
Revenue Growth -0.675
Revenue Per Share 0.001
Sand P52 Week Change 0.36506534
Sector Healthcare
Sector Disp Healthcare
Sector Key healthcare
Shares Outstanding 7,423,432
Shares Percent Shares Out 0.0
Shares Short 211
Shares Short Previous Month Date 1,772,150,400
Shares Short Prior Month 55,704
Short Name Virax Biolabs Group Limited
Short Percent Of Float 0.0
Short Ratio 0.0
Source Interval 15
Symbol VRAX
Target High Price 1.0
Target Low Price 1.0
Target Mean Price 1.0
Target Median Price 1.0
Total Cash 3,437,848
Total Cash Per Share 0.525
Total Debt 537,993
Total Revenue 2,986
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Eps -1.22
Trailing Peg Ratio None
Triggerable 1
Two Hundred Day Average 0.48969
Two Hundred Day Average Change -0.33979
Two Hundred Day Average Change Percent -0.69388795
Type Disp Equity
Volume 3,166,809
Website https://viraxbiolabs.com
Zip ML1 5UH